Malignant Perivascular Epithelioid Cell Neoplasms Withdrawn Phase 2 Trials for Dactolisib (DB11651)

Also known as: Malignant PEComa (Perivascular Epithelioid Cell Tumors) / PEComa, Malignant / Malignant PEComa / Malignant PEComa (perivascular epithelioid cell tumor) / Malignant perivascular epithelioid cell neoplasm / Malignant perivascular epithelioid cell neoplasm (disorder) / Perivascular epithelioid tumor, malignant (morphologic abnormality)

IndicationStatusPhase
DBCOND0144087 (Malignant Perivascular Epithelioid Cell Neoplasms)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01690871A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaTreatment